Amgen Could Block Enbrel Biosimilars For Another Decade As Court Rules Stealth Patents Valid
Executive Summary
Court rejects Sandoz's arguments that patents covering Enbrel's active ingredient and method of manufacture are invalid; decision comes three years after FDA approved Sandoz's biosimilar.